Evotec extends drug discovery alliance with Genentech

(PresseBox) ( Hamburg, )
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has extended its drug discovery alliance with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for three additional years.

The collaboration was initiated in May 2010 and this extension further validates Evotec's technology platform and broad expertise in drug discovery.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'We are delighted and proud that Genentech has decided to extend the current agreement. Both sets of scientists have collaborated very closely over the past few years and this extension is validation of the value we bring to Genentech's discovery programmes.'

FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.